Blood gene test detects 90% of early-stage pancreatic cancers
Researchers at Kanazawa University have developed a blood-based gene expression test that can detect early-stage pancreatic cancer. This non-invasive method aims to improve survival rates by identifying the disease when it is still surgically treatable.
Why it matters
Pancreatic cancer has a notoriously low survival rate due to late detection; this technology could significantly improve patient outcomes.
edited by Gaby Clark , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Early-stage pancreatic cancer detection by a blood test. oward the development of a diagnostic system for early-stage pancreatic cancer: A non-invasive, blood-based gene expression test enables the detection of Stage 0 pancreatic cancer (5-year survival rate: 100% at Kanazawa University Hospital) and StageⅠdisease (5-year survival rate: 74.4%). Credit: Kanazawa University Researchers at Kanazawa University report that blood-based gene expression tests may enable early pancreatic cancer screening and improve long-term survival.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in